The Vanguard Study: Testing a New Way to Screen for Cancer

This study is being done to answer the following question:
How do two new types of blood screening tests for cancer, called multi-cancer detection (MCD) tests work for people who are eligible to be screened for cancer?
This study is the first part of a larger plan to evaluate how well these MCD tests work across different communities in the United States, for detecting a number of different cancers.

For more information, visit: https://clinicaltrials.gov/study/NCT06995898

Inova Schar Cancer - Saville Center Screening and Prevention Center
A division of Inova Fairfax Hospital
8081 Innovation Park Drive 
Fairfax, VA 22031

Inova Primary Care - Fair Oaks 
3650 Joseph Siewick Dr.  
Suite 400  
Falls Church, VA, 22042

• Ages 45-75 years old
• Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment
• Agree to allow collection of information from their medical records for study-related purposes
• Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic
  • Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion
• Additional eligibility in protocol

• Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years
  • Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible
• Ongoing cancer diagnostic work-up as determined by site investigator
• Ongoing participation in another study of an investigational cancer screening test or technology
• Currently breastfeeding or pregnant, or planning to become pregnant in the next year
• Additional ineligibility in protocol